By translating biomedical discoveries into an integrated, personalized treatment program

for children with cancer

By developing cancer-specific predictive tests to guide cancer therapy for each child

By bringing to the clinic new therapies that considers the unique molecular physiology

of the child and their cancer

Our Mission

is to meet this disease head on with better detection, diagnostic tools and kid friendly treatments that

bring hope to all those involved…

THE NICHOLAS CONOR INSTITUTE for Pediatric Cancer Research

THE NICHOLAS CONOR INSTITUTE

Date of Dx: 7/19/05High-Risk Neuroblastoma

Combinatorial Chemotherapy, Surgery & Retinoic Acid Therapy

NED: 2 ½ years post treatment

Beth Anne Baber, Ph.D., Co-founder, President and CEO

Mother of Nicholas “Conor” Boddy

for Pediatric Cancer Research

“Not very many. Radiation was not an option … surgery was not an option. The only thing left washigh intensity chemotherapy.

Often children with his condition are given 10X the adult dose of chemotherapy that obviously leads to long-term side effects … You may not see these effects immediately, these long-term side- effects will occur as they grow into adulthood.”

-Beth Anne Baber, Conor’s MomBurrill Report Patient Perspective Podcast

July 2009

What kind of treatments option does a child like Conor have?

THE NICHOLAS CONOR INSTITUTE for Pediatric Cancer Research

87,000 will die from the disease/yr worldwide

Survivors will suffer from the long-term, side-effects

Treatment choices are few and unpredictable

Rarity of individual childhood cancers discourages expensive commercial research and development

The facts are …1 out of 300 children will be diagnosed before age 20

Worldwide ~160,000 are diagnosed/yr.

The facts are … but we can make an impact

Unacceptable Market Reality

SITUTATION: If the projected revenue is <$800 M/yr, then NO new pediatric oncology drug development.

CURRENT STRATEGY: Piggyback onto adult products for the lack of pediatric targeted therapies AND often give the children 10X the adult dose.

PROBLEM: Small market and modest overlap between adult & childhood cancers.

CURRENT COST: ~ $500,000 to >$2,500,000 to treat each child

Leukemia (30%)

Brain & NS (22.3%)Lymphomas (8%)Neuroblastoma (7.3%)

Other cancers (32.4%)

Our advantage is the value we create

Develop

Validate

Apply

Baseline

6 months to 1 year

Acquire

Identify Technology& Industry Partner(s)

TNCI Value Creation

Time Horizon: 2-5 years

Translate

Research(Other Institutions)

Time

Clinic

Clinical application

TACTiC reduces R&D cost through sharing of resources.

TACTiC creates mini centers of excellence for childhood cancer in the biomedical industry.

TACTiCTM: Non-profit Strategy for Innovation

Obtain funding

•Government•Foundation•Philanthropy

Molecular Dx

CompanyIdentify industry partner

Commercialize or

Identify Partner

TACTiC is flexible and scalable

Establish on-site laboratory

Molecular Dx Company

The Accelerator of Cancer Treatments in Children

TACTiCTM

Prognosys BioSc & others TBA

AltheaDx CollabRx& others TBA

Industry Partners:

Genomics ProteomicsBio-

informatics CDxMDxCenters of Excellence for

Childhood Cancer:

The Nicholas Conor Institute

Academia

Children’s Oncology Group& Clinical Research Centers

International Consortiums

iChanneX & GenVault

Pediatric Cancer Outcome Exchange

TBA TBA

TACTiCTM: Non-profit Strategy for Innovation The advantages of TACTiCTM are many:

Quick start-up with built in capacity;

Provides a focused effort to translate key academic discoveries to the clinic;

Direct transfer of knowledge and expertise between industry and academia;

Economies of scale, sharing of infrastructure and capital equipment leads to lowers indirect cost;

Efficient use of research dollars appeals to funding organizations and donor investors;

Appeals to research institutes that license their discoveries for commercialization;

Allows for flexibility and easily scalable; and,

Aligns with our mission and differentiates The Nicholas Conor Institute from others.

The Nicholas Conor Institute’s Strategic & Patient Advocacy Partners

Children’s Rare Disease Network (CRDN, The Project)• Public awareness for children’s rare diseases, including Childhood Cancer

CureSearch for Children’s Cancer (National Childhood Cancer Foundation, NCCF)

• Support for Children’s Oncology Group• Support for TNCI personalize medicine initiatives• Public awareness for childhood cancer, the need for industry involvement,

and a personalize approach the treating childhood cancer

THE NICHOLAS CONOR INSTITUTEBoard of Directors

Beth Alton Chair of the Board of Directors Founder and CEO of Keene Solutions

Beth Anne Baber, Ph.D., MBA Co-founder and CEO

Martin Latterich, Ph.D. Co-founder and CSO

John Wooley, Ph.D. Assoc. Vice Chancellor of Research-UCSD

Geoff Wahl, Ph.D. Professor at the Salk Institute

Former President of the AACRTrustee of the AACR Foundation

Tony Hunter, Ph.D. Prof. & Director of the Salk Institute Cancer Center

Bud BromleyPresident and COO of Psynomics

Mort Freedman Former Chair of

Steele Children’s Research Center

Jeff WolfFounded and CEO of Wolf Management Consultants

Janet VohariwattFounder and CEO of iChanneX

David GeerdesAttorney at Law

THE NICHOLAS CONOR INSTITUTE for Pediatric Cancer Research

TheNicholasConorInstitute.org (TNCI.org)